Butcher Arthur C

EVP Arthur C Butcher sold 17,313 shares at $101.55 for $1.8M, reducing BSX holdings 42.3%; stock down 8.4% from 52-week high.

Butcher, serving as EVP and Group President of MedSurg & APAC, sold 17,313 shares (17.3K shares) at $101.55 on 2025-12-01, bringing his post-transaction holdings to 23,600 shares (23.6K shares) from 40,913 shares (40.9K shares) — a net reduction of 42.3%. At the current price of $99.02, the stock is -8.4% from its 52-week high of $108.14. His prior five trades at BSX were all sells executed across 2024–2025, with a same-ticker timing pattern of 1 of 5 prior sells well-timed at the 90-day mark; the most recent prior sale on 2025-08-01 saw a 90-day return of -3.9% (well-timed), and the sale before that on 2025-05-01 returned +4.6% over 90 days (poorly timed). Cross-ticker, his seven prior sells averaged a 90d return of +6.1%, though his 90-day well-timed rate was only 14.29%. The fundamental backdrop shows BSX trading at a P/E of 52.67 with strong revenue growth of +17.6% year-over-year, suggesting the stock remains relatively valued despite recent near-term weakness.

EVP Arthur C. Butcher sold 17,313 shares of BSX at $104.63; stock at $106.79; prior BSX sells consistently posted gains.

Arthur C. Butcher, EVP & Group President of MedSurg & APAC, sold 17,313 shares on 2025-08-01 at $104.63, reducing his holdings by 42.3% from 40,913 to 23,600 shares. His five prior sales at BSX have each resulted in subsequent stock appreciation (ranges from +2.0% to +5.4% over 30 days, and +2.7% to +17.0% over 90 days), yet none achieved downside capture at the 90-day mark—indicating this insider's sales pattern has consistently missed declines and coincided with further rallies. The current stock price of $106.79 is -0.9% from its 52-week high of $107.76, and the company reports strong fundamentals with $5.1B in latest quarterly revenue and +17.6% annual growth, though the P/E of 63.19 reflects elevated valuation. This sale extends a recurring pattern but offers no signal of material deterioration or conviction shift, merely continuation of his periodic liquidity reductions.

Butcher (EVP, MedSurg & APAC) sold 17,314 shares at $102.06 for $1.8M, reducing holdings 43.8%

Butcher sold 17.3K shares at $102.06 on 2025-05-01, reducing his position from 39.5K to 22.2K shares—a 43.8% reduction. The current stock price of $104.24 is 1.8% below the 52-week high, and has climbed 16.2% over the past 30 days. At the same ticker, his prior 5 sales generated positive 90-day returns of +3.4%, +2.7%, +17.0%, +13.6%, and +5.5%, with 0 of 5 constituting well-timed sells (where the stock would have declined post-sale). This sale follows the same pattern: subsequent price momentum has been upward, suggesting the sale was not preceded by negative catalysts. BSX itself shows solid fundamentals with $4.7B quarterly revenue, $672.0M net income, and 17.6% annual growth, though the 76.09 P/E reflects elevated valuation expectations.

EVP Arthur Butcher sold 17,313 shares of BSX for $1,762,507.23 on 2025-02-03 near 52-week high

Arthur Butcher, EVP & Group President for Medical Surgery & APAC, executed 2 separate sales on 2025-02-03 totaling 17,313 shares for $1,762,507.23 at blended average price of $101.80, reducing his holdings by 75.9% from 22,815 to 5,502 shares. The sales occurred at prices near the 52-week high of $103.54, with the stock currently trading at $103.54 (+0.0% from that high) and up 14.2% over 30 days and 19.8% over 90 days. His prior 3 trades at this ticker were all sells (2024-11-25, 2024-08-26, 2024-05-28), none of which were well-timed at the 90-day mark, with those prior sales followed by positive returns of +2.0%, +5.4%, and +2.2% respectively at 30 days. The substantial reduction in his position during a period of elevated stock momentum warrants investor attention to whether this reflects a shift in his assessment of valuation or near-term outlook.

EVP Butcher sells 14.0K BSX shares at $89.27; reduces holdings by 93.5% to 978 shares on 2024-11-25.

Arthur C Butcher, EVP & Group President of MedSurg & APAC, liquidated 14,010 shares for $1,250,664.29, reducing his BSX position from 14,988 shares to 978 shares—a 93.5% reduction in holdings. BSX is trading at $89.25, near its 52-week high of $91.50 (only -2.5% below), following strong 30-day (+5.3%) and 90-day (+11.8%) gains. His cross-ticker track record shows 2 prior sells with a well-timed rate of 0.00%, while his same-ticker history at BSX (2 prior sales in Aug and May 2024) also shows a 0.00% well-timed rate at the 90-day mark. The substantial position reduction—from 15.0K to under 1K shares—stands out as a material shift in exposure and merits disclosure scrutiny to confirm no material adverse information prompted the trade.

EVP Arthur Butcher sells 14,012 shares of BSX at $79.25, reducing holdings -56.5% to 10,802 shares ($1.1M transaction)

Butcher, EVP and Group President of MedSurg & APAC, sold 14,012 shares at $79.25 on 2024-08-26, cutting his stake more than in half to 10,802 shares remaining. This is a material reduction in ownership, though the executive retains a meaningful position. The sale occurred near the 52-week high ($79.58), just $0.33 below the cycle peak. In Butcher's single prior BSX transaction on 2024-05-28 (a sale), the stock subsequently rose 5.5% over 90 days—a poorly-timed sell. His cross-ticker track record shows 0 of 1 prior sells were well-timed at the 90-day mark, indicating a pattern of selling before gains rather than before declines. BSX's strong fundamentals—$4.1B quarterly revenue (+12.3% annual growth) and $117.0B market cap—do not suggest external distress.

Director Arthur C Butcher purchases 1,315 shares at $37.99, raising stake to 4,208 shares (+45.5%)

Director Arthur C Butcher acquired 1,315 shares at $37.99 on 2024-08-12, increasing his total holdings from 2,893 to 4,208 shares—a 45.5% increase in personal stake. The purchase occurred at a price 26.7% below the 52-week high of $52.25 and roughly 1% below the current price of $38.29, during a period of recent weakness (30-day and 90-day declines of 9.9% each). While the company shows solid fundamentals with 13.4% annual revenue growth and quarterly revenue of $99.0M, the elevated P/E of 112.62 reflects a stretched valuation. The director's prior cross-ticker track record shows 1 prior sell with an average 30-day return of 2.2%, providing limited basis to assess his predictive accuracy at STAA specifically.